SC
DNA icon

Shay Capital’s Ginkgo Bioworks DNA Stock Holding History

Shay Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Sell
44,842
-5,387
-11% -$45K 0.03% 309
2026
Q1 		$308K Buy
50,229
+6,330
+14% +$52.7K 0.03% 336
2025
Q4 		$365K Buy
43,899
+22,701
+107% +$244K 0.04% 333
2025
Q3 		$309K Buy
21,198
+1,816
+9% +$21.7K 0.03% 303
2025
Q2 		$218K Buy
19,382
+1,124
+6% +$8.71K 0.03% 250
2025
Q1 		$104K Sell
18,258
-4,411
-19% -$44.9K 0.02% 270
2024
Q4 		$223K Buy
+22,669
New +$194K 0.03% 248
2024
Q3 		– Sell
-3,331
Closed -$44.5K – 355
2024
Q2 		$44.5K Buy
3,331
+2,224
+201% +$66.4K 0.01% 249
2024
Q1 		$51.4K Buy
1,107
+431
+64% +$22.3K 0.01% 351
2023
Q4 		$45.7K Hold
676
– – 0.01% 252
2023
Q3 		$49K Sell
676
-55
-8% -$4.4K 0.01% 313
2023
Q2 		$54.4K Hold
731
– – 0.01% 361
2023
Q1 		$38.9K Buy
731
+376
+106% +$23.8K 0.01% 384
2022
Q4 		$24K Buy
+355
New +$32.7K 0.01% 255
2022
Q3 		– Sell
-301
Closed -$29K – 391
2022
Q2 		$29K Buy
+301
New +$36.7K 0.01% 384

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Shay Capital's DNA Position: Q2 2026 in Review

Shay Capital reduced its Ginkgo Bioworks (DNA) stake by 11% in Q2 2026, selling an estimated $45K and leaving 44,842 shares worth $444K. The position accounts for 0.03% of the portfolio, ranked #309.

Shay Capital first reported a position in DNA in Q2 2022 and has held it in 15 quarters since. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Shay Capital held 44,842 shares of Ginkgo Bioworks worth $444K as of Q2 2026.
  • Shay Capital sold 5,387 Ginkgo Bioworks shares in Q2 2026, an estimated $45K.
  • Ginkgo Bioworks made up 0.03% of Shay Capital's portfolio in Q2 2026, its #309 holding.
  • Shay Capital first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 15 quarters since.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.